X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUVEN LIFE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUVEN LIFE FRESENIUS KABI ONCO./
SUVEN LIFE
 
P/E (TTM) x 22.1 19.3 114.6% View Chart
P/BV x 3.1 3.6 86.9% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   SUVEN LIFE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUVEN LIFE
Mar-16
FRESENIUS KABI ONCO./
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs176339 52.0%   
Low Rs79144 54.4%   
Sales per share (Unadj.) Rs37.739.2 96.0%  
Earnings per share (Unadj.) Rs5.17.5 68.3%  
Cash flow per share (Unadj.) Rs6.78.8 76.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.549.0 86.8%  
Shares outstanding (eoy) m158.23127.28 124.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.2 54.9%   
Avg P/E ratio x25.032.4 77.2%  
P/CF ratio (eoy) x18.927.5 68.8%  
Price / Book Value ratio x3.04.9 60.7%  
Dividend payout %026.8 0.0%   
Avg Mkt Cap Rs m20,13530,732 65.5%   
No. of employees `0001.21.0 120.8%   
Total wages/salary Rs m703416 168.9%   
Avg. sales/employee Rs Th5,176.25,236.1 98.9%   
Avg. wages/employee Rs Th610.4436.5 139.9%   
Avg. net profit/employee Rs Th699.6995.5 70.3%   
INCOME DATA
Net Sales Rs m5,9634,995 119.4%  
Other income Rs m18194 9.3%   
Total revenues Rs m5,9815,189 115.3%   
Gross profit Rs m1,4301,233 116.0%  
Depreciation Rs m258167 154.2%   
Interest Rs m-2654 -48.0%   
Profit before tax Rs m1,2161,205 101.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342255 134.2%   
Profit after tax Rs m806950 84.9%  
Gross profit margin %24.024.7 97.2%  
Effective tax rate %28.121.2 132.9%   
Net profit margin %13.519.0 71.1%  
BALANCE SHEET DATA
Current assets Rs m5,1024,986 102.3%   
Current liabilities Rs m2,3851,042 228.9%   
Net working cap to sales %45.679.0 57.7%  
Current ratio x2.14.8 44.7%  
Inventory Days Days15061 246.0%  
Debtors Days Days11339 289.5%  
Net fixed assets Rs m5,1483,126 164.7%   
Share capital Rs m158127 124.3%   
"Free" reserves Rs m6,5563,717 176.3%   
Net worth Rs m6,7326,236 107.9%   
Long term debt Rs m952432 220.3%   
Total assets Rs m10,3888,079 128.6%  
Interest coverage x-45.823.2 -197.1%   
Debt to equity ratio x0.10.1 204.1%  
Sales to assets ratio x0.60.6 92.8%   
Return on assets %7.512.4 60.4%  
Return on equity %12.015.2 78.6%  
Return on capital %14.618.9 77.4%  
Exports to sales %74.587.5 85.1%   
Imports to sales %24.812.2 202.6%   
Exports (fob) Rs m4,4414,371 101.6%   
Imports (cif) Rs m1,477611 241.9%   
Fx inflow Rs m5,2984,666 113.5%   
Fx outflow Rs m1,772942 188.1%   
Net fx Rs m3,5253,724 94.7%   
CASH FLOW
From Operations Rs m1,274922 138.2%  
From Investments Rs m-1,204-619 194.4%  
From Financial Activity Rs m-196-698 28.1%  
Net Cashflow Rs m-126-396 31.9%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   42,599 37,287 114.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS